Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.